A mannosylated cell-penetrating peptide-graft-polyethylenimine as a gene delivery vector

Microneedles: an innovative platform for gene delivery

“…In contrast, those treated with DNA complexes lacking the mannose ligand exhibited less than 30 % GFP expression in this cell population at all time points investigated confirming the ability of this ligand to enhance cellular uptake in the target cell population. CD11c-negative nonDCs displayed negligible GFP expression, confirming this treatment can specifically target DCs through mannosylation of the DNA delivery vector, an important antigen-presenting cell population for initiating immune responses in vivo [32]. Subsequent to these encouraging results in vivo, the group further investigated this delivery system as a method for cancer immunotherapy.…”

“…The inclusion of a receptor-specific ligand in the delivery vector facilitates binding to the target cell surface receptors, facilitating receptormediated endocytosis of the DNA-containing complex. In an attempt to incorporate specific cell targeting, Hu et al (2014) developed a mannosylated cell-penetrating peptide-graftpolyethylenimine (Man-PEI) as a gene delivery vector to target antigen-presenting cells with mannose receptors, used in conjunction with a solid MN delivery system in vivo [32]. Man-PEI/pEGFP-N2 complexes containing 50 μg DNA in 100 μl PBS was topically applied to an area of shaved abdominal skin on BALB/c mice, with MN pre-treatment followed by immunotherapy.…”

Cationic Polymers for the Delivery of Therapeutic Nucleotides

“…More attention must be given to develop peptide-grafted PEIs such as mannosylated cell-penetrating peptide-graft-polyethyleneimine (Hu et al 2014) and TAT peptide-modified PEI (Yamano et al 2014). The genotoxicity of endocytosed PEI NPs is associated with the production of reactive oxygen species (ROS), which causes DNA damage without apparently affecting cell viability.…”

Synthesis of Mannosylated Polyethylenimine and Its Potential Application as Cell-Targeting Non-Viral Vector for Gene Therapy

“…Prior to analysis, the PEI/DNA complexes with N/P ratios in the range of 1:1 to 30:1 were prepared according to the conditions described previously [14]. All of these analyses were conducted in triplicate.…”

“…DC2.4 and HeLa cells were seeded into 96-well plates (5 × 10 3 cells/well) and incubated for 24 h at 37 °C with 5% CO2, as previously described [14]. By keeping the amount of DNA as constant (1 µg/well ), the PEI/DNA complexes of the different PEI derivates with N/P ratios in the range of 1 to 40 were then added to the cells, and the resulting mixtures were incubated for 24 h at 37 °C with 5% CO2.…”